Skip to main content
. Author manuscript; available in PMC: 2015 Nov 5.
Published in final edited form as: Sci Transl Med. 2014 Nov 5;6(261):261ra152. doi: 10.1126/scitranslmed.3009318

Fig. 6. Reversal of MDR1-mediated drug efflux in vivo with topical application of the MDR1 inhibitor, HM30181, to heterogeneous tumors.

Fig. 6

(A) Eribulin-BFL accumulation in heterogeneous tumors containing MDR1-expressing cells (arrows), with and without topical administration of HM30181 directly to the tumor site. Images are representative of 3 mice. (B) Single-cell quantification of eribulin-BFL accumulation in wild type and resistant single cells, with or without HM30181 (min-max normalized per frame). Horizontal lines indicate median uptake per unit area and all individual data points are shown; an average of 103 cells were analyzed per group. (C) Relative drug increase in wild type and MDR1-expressing (resistant) cells with topical application of HM30181. Data are the ratio of median drug accumulation per cell type before and after topical application of HM30181 in n = 3 mice. All P values determined according to a two-sided unpaired t-test, assuming equal SD.